Adult Vaccines Market Analysis: Major Segments, Strategic Developments, and Leading Companies

The adult vaccines market is poised for significant expansion as healthcare continues to prioritize immunization for aging populations. Advances in vaccine technology and growing public health initiatives are setting the stage for robust market growth through the end of the decade. Below, we explore the market's anticipated size, key players, prevailing trends, and detailed segment analysis.

Projected Market Valuation and Growth Trajectory of the Adult Vaccines Market
Forecasts indicate that the adult vaccines market will reach a valuation of $37.51 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.2%. This upward trend is largely driven by technological innovations in mRNA and recombinant vaccines, increased funding for adult immunization programs, enhancements in cold chain logistics, heightened awareness about vaccine-preventable diseases, and strategic collaborations between pharmaceutical and biotech firms. Additionally, prominent evolving trends include rising consciousness about adult vaccination, expansion of immunization initiatives, development of combination vaccines, growth in vaccines targeting chronic conditions, and increasing demand for travel and occupational vaccines.

Leading Participants in the Adult Vaccines Market
Several prominent companies dominate the adult vaccines landscape worldwide. These include GlaxoSmithKline PLC, Merck & Co, Sanofi Pasteur, Pfizer Inc, Commonwealth Serum Laboratories Limited, Johnson & Johnson, Serum Institute of India, AstraZeneca PLC, Novartis AG, Protein Sciences Corporation, Emergent BioSolutions Inc., Bavarian Nordic A/S, Dynavax Technologies Corporation, Novavax Inc, Medimmune LLC, BioNTech SE, Moderna, Inovio Pharmaceuticals, Sinovac, Valneva SE, Biological E Limited, Panacea Biotec, Shenzhen Kangtai Biological Products, Beijing Tiantan Biological Products, Hualan Biological Engineering, Chengdu Institute of Biological Products, Bharat Biotech International Limited, and Takeda Pharmaceutical Company Limited.

Strategic Expansion Moves in the Adult Vaccines Sector
In December 2023, AstraZeneca, a UK-based leader in respiratory and immune-therapeutic vaccines, acquired US-based Icosavax in a deal valued up to US$1.1 billion. This acquisition aims to broaden AstraZeneca's adult vaccine portfolio by integrating Icosavax's virus-like particle (VLP) vaccine platform and advancing its lead candidate, IVX A12, a combination vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in older adults. Icosavax specializes in developing VLP vaccines focusing on respiratory infections in adult populations.

Technological Innovations Setting Future Directions in Adult Vaccines
The adult vaccines market is witnessing a strong focus on technological breakthroughs, especially mRNA-based vaccines that enable rapid and precise immune responses. These vaccines use messenger RNA encapsulated in lipid nanoparticles to instruct human cells to produce viral proteins, effectively triggering immunity without live or weakened virus components. For example, in May 2024, Moderna, a US biotech company, received FDA approval for mRESVI, an mRNA vaccine against respiratory syncytial virus (RSV) for adults aged 60 and above. The vaccine encodes the prefusion F glycoprotein of RSV and is delivered via single-dose, pre-filled syringes. This innovation enhances antibody production, safety, and efficacy compared to traditional vaccines, broadening options for adult immunization.

Detailed Segment Analysis of the Adult Vaccines Market
This market is segmented based on several factors:
1) Vaccine Type: Monovalent and Multivalent vaccines
2) Technology: Live attenuated vaccines, inactivated viral or bacterial vaccines, toxoid vaccines, recombinant vaccines, and conjugate vaccines
3) Application Areas: Influenza, DPT (diphtheria, pertussis, tetanus), human papillomavirus, zoster, pneumococcal, and hepatitis
4) End Users: Healthcare firms and hospitals
Further subcategories include:
- Monovalent vaccines broken down into single antigen vaccines and specific disease vaccines
- Multivalent vaccines divided into combination vaccines and multi-antigen vaccines

This comprehensive segmentation provides clarity on the various facets shaping the adult vaccines market and its evolving opportunities.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.